# Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

> **NCT00728845** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 8 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** carboplatin
- **DRUG:** hydroxychloroquine
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00728845
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06-16
- **Primary completion:** 2010-12-21
- **Final completion:** 2010-12-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728845, "Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00728845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*